Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Inorg Biochem ; 103(11): 1497-503, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19740543

RESUMEN

In acid soils, aluminium (Al) toxicity and phosphate (Pi) deficiency are the most significant constraints on plant growth. Al inhibits cell growth and disrupts signal transduction processes, thus interfering with metabolism of phospholipase C (PLC), an enzyme involved in second messenger production in the cell. Using a Coffea arabica suspension cell model, we demonstrate that cell growth inhibition by Al toxicity is mitigated at a high Pi concentration. Aluminium-induced cell growth inhibition may be due to culture medium Pi deficiency, since Pi forms complexes with Al, reducing Pi availability to cells. Phosphate does not mitigate inhibition of PLC activity by Al toxicity. Other enzymes of the phosphoinositide signal transduction pathway were also evaluated. Aluminium disrupts production of second messengers such as inositol 1,4,5-trisphosphate (IP(3)) and phosphatidic acid (PA) by blocking PLC activity; however, phospholipase D (PLD) and diacylglycerol kinase (DGK) activities are stimulated by Al, a response probably aimed at counteracting Al effects on PA formation. Phosphate deprivation also induces PLC and DGK activity. These results suggest that Al-induced cell growth inhibition is not linked to PLC activity inhibition.


Asunto(s)
Aluminio/farmacología , Coffea/efectos de los fármacos , Fosfatos/farmacología , Transducción de Señal/efectos de los fármacos , Fosfolipasas de Tipo C/metabolismo , Aluminio/análisis , Células Cultivadas , Coffea/crecimiento & desarrollo , Coffea/metabolismo , Diacilglicerol Quinasa/efectos de los fármacos , Diacilglicerol Quinasa/metabolismo , Inositol 1,4,5-Trifosfato/antagonistas & inhibidores , Inositol 1,4,5-Trifosfato/metabolismo , Ácidos Fosfatidicos/antagonistas & inhibidores , Ácidos Fosfatidicos/metabolismo , Fosfolipasa D/efectos de los fármacos , Fosfolipasa D/metabolismo , Transducción de Señal/fisiología , Fosfolipasas de Tipo C/antagonistas & inhibidores
2.
Curr Drug Targets ; 9(8): 626-40, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18691010

RESUMEN

Diacylglycerol (DAG) kinase (DGK) modulates the balance between the two signaling lipids, DAG and phosphatidic acid (PA), by phosphorylating (consuming) DAG to yield PA. Ten mammalian DGK isozymes have been identified to date. In addition to two or three cysteine-rich C1 domains (protein kinase C-like zinc finger structures) commonly conserved in all DGKs, these isoforms possess a variety of regulatory domains of known and/or predicted functions, such as a pair of EF-hand motifs, a pleckstrin homology domain, a sterile alpha motif domain, a MARCKS (myristoylated alanine-rich C kinase substrate) phosphorylation site domain and ankyrin repeats. Recent studies have revealed that DGK isozymes play pivotal roles in a wide variety of mammalian signal transduction pathways conducting growth factor/cytokine-dependent cell proliferation and motility, seizure activity, immune responses, cardiovascular responses and insulin receptor-mediated glucose metabolism. It is suggested that several DGK isozymes can serve as potential drug targets for cancer, epilepsy, autoimmunity, cardiac hypertrophy, hypertension and type II diabetes. Unfortunately, there are no DGK isozyme-specific inhibitors/activators at present. Development of these compounds is eagerly awaited for the development of novel drugs targeting DGKs.


Asunto(s)
Diacilglicerol Quinasa/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Transducción de Señal , Animales , Diacilglicerol Quinasa/metabolismo , Diseño de Fármacos , Humanos , Isoenzimas/metabolismo , Ácidos Fosfatidicos/metabolismo , Fosforilación
3.
J Neurosci Res ; 81(2): 244-52, 2005 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-15948152

RESUMEN

Insulin receptor associated with the cerebral cortex (CC) has been shown to be involved in brain cognitive functions. Furthermore, deterioration of insulin signaling has been associated with age-related brain degeneration. We have reported previously that aging stimulates phospholipase D/phosphatidate phosphohydrolase 2 (PLD/PAP2) pathway in CC synaptosomes from aged rats, generating a differential availability of their reaction products: diacylglycerol (DAG) and phosphatidic acid (PA). The aim of this work was to determine the effect of aging on DAG kinase (DAGK), as an alternative pathway for PA generation, and to evaluate the effect of insulin on PLD/PAP2 pathway and DAGK. PLD, PAP2, and DAGK activities were measured using specific radiolabeled substrates in CC synaptosomes from adult (4 months old) and aged rats (28 months old). In adult animals, in the presence of the tyrosine phosphatase inhibitor (sodium o-vanadate), insulin stimulated PLD activity at 5 min incubation. DAGK activity was also increased at the same time of incubation and PAP2 was inhibited. In aged animals, PLD activity was not modified by the presence of insulin plus vanadate, PAP2 was inhibited, and DAGK was stimulated by the hormone. Insulin, vanadate, and the combination of both induced protein tyrosine phosphorylation in adult CC synaptosomes. Aged rats showed a lower level of protein phosphorylation with respect to adult rats. Our results show that insulin modulates PA and DAG availability through the regulation of PLD/PAP2 and DAGK pathways in adult rat CC synaptosomes. Additionally, we demonstrated that PA and DAG generation is regulated differentially by insulin during aging.


Asunto(s)
Envejecimiento/fisiología , Diacilglicerol Quinasa/metabolismo , Insulina/fisiología , Fosfatidato Fosfatasa/metabolismo , Fosfolipasa D/metabolismo , Sinaptosomas/enzimología , Animales , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/enzimología , Diacilglicerol Quinasa/efectos de los fármacos , Diglicéridos/metabolismo , Inhibidores Enzimáticos/farmacología , Fosfatidato Fosfatasa/efectos de los fármacos , Ácidos Fosfatidicos/metabolismo , Fosfolipasa D/efectos de los fármacos , Ratas , Ratas Wistar , Receptor de Insulina/efectos de los fármacos , Receptor de Insulina/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Sinaptosomas/efectos de los fármacos , Vanadatos/farmacología
4.
Am J Chin Med ; 32(2): 245-56, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15315262

RESUMEN

Prevention of diabetic gastrointestinal dysfunction is of utmost importance. The present study demonstrated that diacylglycerol kinase (DGK) activity in diabetic gastric smooth muscle in the resting state was approximately 3.5-fold greater than that in controls. However, oral administration of TJ-43 (1% of food intake) or subcutaneous insulin injection (12 units/kg/day) in streptozotocin-induced diabetic rats (DM) for 2 weeks prevented DGK abnormalities based on the control level. Increased DGK activity in the resting state of DM was inhibited significantly by R59022, neomycin or staurosporine; in contrast, these drugs did not affect DGK activity in controls, insulin-treated DM or TJ-43-treated DM. In controls, the endogenous phosphatidic acid (PA) level was inhibited significantly by R59022 or neomycin but not affected by staurosporine. On the other hand, these three drugs significantly inhibited endogenous PA levels in DM, and neomycin significantly inhibited endogenous PA levels in insulin-treated and TJ-43-treated DM. This suggests that TJ-43 could prevent alteration of DGK activity and PA formation without reduction of blood glucose levels. Moreover, these effects were greater than those of insulin treatment. Results suggested that TJ-43 treatment influenced the hyperreactivity of DGK and DAG formation via phospholipase C activity. In conclusion, TJ-43 can be recommended with respect to enhancement of the quality of life in patients displaying diabetic gastrointestinal complications.


Asunto(s)
Complicaciones de la Diabetes , Diacilglicerol Quinasa/efectos de los fármacos , Diacilglicerol Quinasa/farmacología , Medicamentos Herbarios Chinos/farmacología , Músculo Liso/enzimología , Estómago/fisiología , Animales , Antibióticos Antineoplásicos/administración & dosificación , Modelos Animales de Enfermedad , Masculino , Contracción Muscular/efectos de los fármacos , Ratas , Ratas Wistar , Transducción de Señal , Estreptozocina/administración & dosificación
5.
Am J Kidney Dis ; 38(4 Suppl 1): S178-81, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11576950

RESUMEN

Diabetic nephropathy is characterized functionally by glomerular hyperfiltration and albuminuria and histologically by the expansion of glomerular mesangium. We and others have found that protein kinase C (PKC) is activated through an increase in de novo synthesis of diacylglycerol (DAG) from glucose in glomerular mesangial cells cultured under high glucose conditions and in glomeruli of diabetic rats. The activation of PKC could activate further various intracellular signal transduction systems, such as extracellular regulated kinase (ERK). The activation of the DAG-PKC-ERK pathway is considered to be one of the important molecular mechanisms of the development and progression of diabetic nephropathy. To prove this hypothesis, we examined whether the inhibition of the DAG-PKC-ERK pathway could prevent the development of glomerular dysfunction in diabetic animals. First, we found that thiazolidinedione compounds could inhibit PKC activation by activating DAG kinase. Thiazolidinedione compounds were able to prevent glomerular hyperfiltration, albuminuria, and excessive production of extracellular matrix proteins in glomeruli in streptozotocin-induced diabetic rats, a model for type 1 diabetes. Second, we tried to inhibit PKC directly by oral administration of PKC beta inhibitor. PKC beta inhibitor could prevent albuminuria and mesangial expansion in db/db mice, a model for type 2 diabetes. These results confirmed the importance of the activation of the DAG-PKC-ERK pathway in the development of glomerular dysfunction in diabetes.


Asunto(s)
Nefropatías Diabéticas/metabolismo , Diacilglicerol Quinasa/efectos de los fármacos , Mesangio Glomerular/metabolismo , Isoenzimas/antagonistas & inhibidores , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas de Plantas/metabolismo , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/metabolismo , Tiazolidinedionas , Animales , Cromanos/farmacología , Diabetes Mellitus Tipo 2 , Nefropatías Diabéticas/prevención & control , Progresión de la Enfermedad , Activación Enzimática , Mesangio Glomerular/efectos de los fármacos , Mesangio Glomerular/patología , Ratones , Pioglitazona , Proteínas de Plantas/efectos de los fármacos , Proteína Quinasa C beta , Ratas , Transducción de Señal , Tiazoles/farmacología , Troglitazona
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA